טוען...
Preclinical Evidence of Alzheimer Changes: Convergent Cerebrospinal Fluid Biomarker and Fluorodeoxyglucose Positron Emission Tomography Findings
BACKGROUND: Alterations in cerebrospinal fluid (CSF) tau and β–amyloid peptide 1–42 (Aβ(42)) levels and rates of cerebral glucose (CMRglu) on fluorodeoxyglucose positron emission tomography (FDG PET) occur years before clinical symptoms of Alzheimer’s disease (AD) become manifest, but their relation...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2718788/ https://ncbi.nlm.nih.gov/pubmed/19433663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2009.59 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|